Next Treatments
Back to Eczema

camoteskimab

TypeInjection StagePhase 2 Latest updateMay 28, 2026Phase 2 study started

What stands out

New approach in eczema

  • Binds to IL-18, an inflammation signal that rallies immune cells
Derived from FDA substance registry · UniProt Q14116 ·
11 US eczema labels (Cibinqo, Eucrisa, Adquey, Dupixent, Ebglyss, Nemluvio, Zoryve, Opzelura, Vtama, Adbry, Rinvoq)
· This is a summary of public records for informational purposes only. It is not medical advice.

History

Earliest recorded event: May 1, 2024. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • May 28, 2026Phase 2 trial startedA Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis ClinicalTrials.gov NCT07599813
  • Aug 12, 2025Phase 2 trial completedA Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06436183
  • Mar 26, 2025Phase 2 main data collectedA Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06436183
  • May 1, 2024Phase 2 trial startedA Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06436183

Sources

Trials